New Launch3 Oct 2025, 06:21 pm
Lupin Launches Liraglutide Injection in the United States
AI Summary
Global pharma major Lupin Limited has announced the launch of Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen, in the United States. The product is bioequivalent to Victoza® Injection, 18 mg/3 mL (6 mg/mL) of Novo Nordisk Inc. It is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older, with type 2 diabetes mellitus. The estimated annual sale of the reference listed drug in the U.S. is USD 350 million. This launch marks a significant milestone in enhancing Lupin's portfolio of complex injectables and highlights the company's continued commitment to making essential therapies more accessible for patients.
Key Highlights
- Lupin launched Liraglutide Injection, 18 mg/3 mL (6 mg/mL) Single-Patient-Use Prefilled Pen, in the United States.
- The product is bioequivalent to Victoza® Injection, 18 mg/3 mL (6 mg/mL) of Novo Nordisk Inc.
- It is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients aged 10 years and older, with type 2 diabetes mellitus.
- The estimated annual sale of the reference listed drug in the U.S. is USD 350 million.
- This launch marks a significant milestone in enhancing Lupin's portfolio of complex injectables.